| 摘要 |
New lamellarins are provided of the general formula III wherein X is selecte d from the group consisting of N, O and S; wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from the group consisting of H, OH , OR~, SH, SR~, SO2R~, NHR~, N(R~)2, N=R', NHCOR', N(COR~)2, NHS02R~, N02, PO(R~2, P02R', C(=0)H, C(=0)R', C02H, C02R~, OPO(R~)2, OP02R', OC(=0)H, OC(=0)R~, N=C(R')2, substituted or unsubstituted C1-C12 alkyl, substituted o r unsubstituted C1-C12 haloalkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, N02, NH2, SH, CN, halogen, =0, C(=0)H, C(=O)CH3, C02H, C(=0)R', substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2 - C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-C18 alkoxyl, substituted or unsubstituted C1-C18 aminoalkyl, substituted or unsubstituted C1-C18 aminoacid, substituted or unsubstituted C1-C18 thioalky l, substituted or unsubstituted C1-C18 alkylsulfinyl, substituted or unsubstituted C1-C18 alkylsulfonyl; wherein the pairs of groups R1 and R2, R 2 and R3, R3 and R4, R3 and R9, R4 and R9, R9 and R5, R9 and R6, or R6 and R7, R7 and R8 may be joined into a carbocyclic or heterocyclic ring system; and the dotted line represents an single or double bond; or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.
|
